Crdl stock price short interest has declined

CRDL stock price short interest has declined, which often signals reduced bearish sentiment. If fundamentals align, the short covering could accelerate price recovery. Because Cardiol Therapeutics isn't currently generating revenue, we consider it an early-stage business. Nonetheless, we can still examine its cash burn trajectory as part of our assessment of its cash burn situation. Over the last year its cash burn actually increased by a very significant 68%. Oftentimes, increased cash burn simply means a company is accelerating its business development, but one should always be mindful that this causes the cash runway to shrink. Clearly, however, the crucial factor is whether the company will grow its business going forward. For that reason, it makes a lot of sense to take a look at our analyst forecasts for the company . The global medical cannabis market is projected to surpass the $130 billion mark by the end of 2032, primarily driven by the increasing acceptance of cannabis for therapeutic purposes. As one of the few companies developing a CBD-based product for heart diseases, Cardiol Therapeutics is positioning itself within this expanding market. CRDL stock price fluctuations are closely correlated with Nasdaq Biotech Index performance. Short-term forecasts project price stabilization before a possible next leg higher in Q